Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.

Proceedings of the National Academy of Sciences of the United States of America
Richard T WilliamsCharles J Sherr

Abstract

Mouse bone marrow cells transduced with retroviral vectors encoding either of two oncogenic Bcr-Abl isoforms (p210(Bcr-Abl) and p185(Bcr-Abl)) induce B cell lympholeukemias when transplanted into lethally irradiated mice. If the activity of the Arf tumor suppressor is compromised, these donor cells initiate a much more highly aggressive and rapidly fatal disease. When mouse bone marrow cells expressing Bcr-Abl are placed in short-term cultures selectively designed to support the outgrowth of pre-B cells, only those lacking one or two Arf alleles can initiate lympholeukemias when inoculated into immunocompetent, syngeneic recipient mice. Although the ABL kinase inhibitor imatinib mesylate (Gleevec) provides highly effective treatment for BCR-ABL-positive chronic myelogenous leukemia, it has proven far less efficacious in the treatment of BCR-ABL-positive acute lymphoblastic leukemias (ALLs), many of which sustain deletions of the INK4A-ARF (CDKN2A) tumor suppressor locus. Mice receiving Arf-/- or Arf+/- p210(Bcr-Abl)-positive pre-B cells do not achieve remission when maintained on high doses of oral imatinib therapy and rapidly succumb to lympholeukemia. Although cells expressing the Bcr-Abl kinase can proliferate in the absence...Continue Reading

References

Sep 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J McLaughlinO N Witte
Jan 1, 1987·Methods in Enzymology·C A Whitlock, O N Witte
Jan 1, 1994·Current Biology : CB·T JacksR A Weinberg
Feb 1, 1994·Hybridoma·S J VallanceC J Sherr
Aug 8, 1998·Genes & Development·E de StanchinaS W Lowe
Sep 23, 1998·Nature·I PalmeroM Serrano
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·A RadfarN Rosenberg
Oct 29, 1999·Genes & Development·C M EischenJ L Cleveland
Aug 2, 2001·Proceedings of the National Academy of Sciences of the United States of America·D H RandleM F Roussel
Mar 14, 2002·Proceedings of the National Academy of Sciences of the United States of America·Robyn N McKellerStephen X Skapek
Sep 3, 2002·Cancer Cell·Charles J Sherr, Frank McCormick
Jul 17, 2004·Science·Martin Enserink
Aug 19, 2004·Cell·Merel E Valk-LingbeekMaarten van Lohuizen
Jan 28, 2005·Hybridoma and Hybridomics·David BertwistleMartine F Roussel
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott A Armstrong, A Thomas Look

❮ Previous
Next ❯

Citations

Feb 14, 2012·Current Hematologic Malignancy Reports·Tomasz Skorski
Apr 25, 2012·Current Hematologic Malignancy Reports·Ilaria IacobucciGiovanni Martinelli
Sep 19, 2008·Leukemia·N MisaghianJ A McCubrey
Dec 28, 2010·Nature Chemical Biology·Hai JiangMichael T Hemann
Oct 6, 2007·Nature Medicine·Charles L Sawyers
Feb 2, 2011·Nature Reviews. Drug Discovery·Alfonso Quintás-CardamaSrdan Verstovsek
Sep 10, 2010·The Journal of Biological Chemistry·Yanbin ZhengStephen X Skapek
Sep 1, 2007·Genes & Development·Richard T WilliamsCharles J Sherr
Sep 12, 2008·Annual Review of Pathology·Michael A Teitell, Pier Paolo Pandolfi
Dec 7, 2007·The Journal of Clinical Investigation·Michael T DebiesEdward J Gunther
Jul 2, 2010·The Journal of Clinical Investigation·Danilo PerrottiTomasz Skorski
Feb 28, 2009·Blood·Kathleen CullionMichelle A Kelliher
Aug 13, 2011·Clinical Medicine Insights. Oncology·Pankaj TanejaKazushi Inoue
Feb 26, 2014·The Journal of Experimental Medicine·David A NathansonCaius G Radu
Feb 7, 2014·Current Hematologic Malignancy Reports·Andreas Burchert
Feb 11, 2012·EMBO Molecular Medicine·Boris KovacicHartmut Beug
Jul 13, 2007·Proceedings of the National Academy of Sciences of the United States of America·Sven RottenbergPiet Borst
Oct 24, 2006·Proceedings of the National Academy of Sciences of the United States of America·Sylvie GiuriatoDean W Felsher
Nov 2, 2006·Proceedings of the National Academy of Sciences of the United States of America·Yiguo HuShaoguang Li
Nov 29, 2013·Genes & Development·Junwei ShiChristopher R Vakoc
Feb 10, 2016·Cancer Cell·Ilaria IacobucciCharles G Mullighan
Dec 23, 2008·Seminars in Hematology·Charles G Mullighan, James R Downing
Aug 9, 2007·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Andreas Burchert
Jun 3, 2009·International Journal of Laboratory Hematology·C G Mullighan
Jan 22, 2008·Journal of Cellular and Molecular Medicine·Shaoguang Li, Dongguang Li
Sep 1, 2015·Cancer Cell·Michelle L ChurchmanCharles G Mullighan
Apr 29, 2016·JCI Insight·Michelle L ChurchmanCharles G Mullighan
Aug 25, 2015·Clinical Lymphoma, Myeloma & Leukemia·Simona SoveriniGiovanni Martinelli
Feb 15, 2014·Biochimica Et Biophysica Acta·Leonard B MaggiJason D Weber

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.